Posted: August 14, 2019 Mark A. Socinski, MD, executive medical director of AdventHealth Cancer Institute, spoke with the IASLC Lung Cancer News about his personal recommendations for TKI-refractory disease, especially for patients with EGFR mutations. He discussed the latest IMpower150 data,1 as well as the U.S. Food and Drug Administration’s (FDA’s) decision not to approve this…

Posted: August 14, 2019 Lorlatinib, a smallmolecule inhibitor of ALK and ROS1, was granted accelerated U.S. Food and Drug Administration approval in November 2018 for patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor or whose disease has progressed on alectinib or ceritinib as the first ALK…

By Christian Rolfo, MD, PhD, MBA, Dr.h.c., and Lori Alexander, MTPW, ELS, MWC Posted: August 14, 2019 Targeted therapy has become the standard of care in patients with advanced NSCLC and oncogenic drivers, and tissue biopsy has emerged as the gold standard in the molecular diagnosis of the disease. Guidelines recommend that all patients with newly…

By Emily F. Collier, MD; Roy S. Herbst, MD, PhD; and Sarah B. Goldberg, MD, MPH Posted: August 14, 2019 Dr. Emily F. Collier Dr. Roy S. Herbst Dr. Sarah B. Goldberg KEYNOTE-010 is an open-label phase II/ III study that compared pembrolizumab (2 mg/kg or 10 mg/kg every 3 weeks) with docetaxel in previously treated…

Posted: August 14, 2019 People diagnosed with lung cancer do not have to live close to a major cancer center to get a second opinion from one of its experts, thanks to a growing number of remote second-opinion (RSO) programs. “What is offered in remote second-opinion programs can vary, but the one commonality is that the…

Posted: May 27, 2019 ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a large umbrella trial evaluating patients with early-stage NSCLC who have undergone complete tumor resection. As a whole, the trial will examine the role of erlotinib for those patients with EGFR mutations, crizotinib for those patients who have ALK rearrangements, and…

By Paul A. Bunn Jr., MD Posted: May 27, 2019 It is indeed an exciting time in lung cancer therapeutics, and we have reasons to be optimistic. To put these advances in context, I remember the early days (1970s) of lung cancer research at the National Cancer Institute, when we conducted 12 consecutive phase II trials…

By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to available therapies for malignant pleural mesothelioma (MPM). Luckily, a renewed interest in MPM with emphasis on immunotherapy has led to several phase II and III…

Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that the IASLC-LATAM (Latin American) Group organized a BWLCC in Lima. More than 160 attendees were provided with the most scientifically important presentations from the IASLC…

Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes in the study and management of all forms of lung cancer. Dr. Hanna spoke with the IASLC Lung Cancer News in detail about the questions—…